Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HSV thymidine kinase gene therapy

X
Drug Profile

HSV thymidine kinase gene therapy

Alternative Names: Retrovector™

Latest Information Update: 22 Jul 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AVAX Technologies; Edison Biotechnology Institute; Novartis; Scientific Institute San Raffaele; Universite Pierre et Marie Curie
  • Developer AVAX Technologies; Aventis Gencell; Edison Biotechnology Institute; Human Gene Therapy Research Institute (Des Moines); Novartis; Scientific Institute San Raffaele
  • Class Gene therapies
  • Mechanism of Action Thymidine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Brain cancer; Glioma; Graft-versus-host disease; Leukaemia; Liver cancer; Lymphoma; Malignant melanoma; Mesothelioma; Multiple myeloma; Ovarian cancer; Renal cancer

Most Recent Events

  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 20 May 2002 Interneuron Pharmaceuticals is now called Indevus Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top